News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ariad Pharmaceuticals, Inc. (ARIA) Announces Initial Data on AP26113, Investigational Dual-Inhibitor of ALK and EGFR, to be Presented at the ESMO 2012 Congress of the European Society for Medical Oncology


9/17/2012 9:38:12 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the initial data from its Phase 1/2 trial of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), will be presented at the ESMO 2012 Congress of the European Society for Medical Oncology (ESMO) being held in Vienna, Austria, September 28 to October 2, 2012.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES